$12.53
-0.75-5.65%
Last update: Nov 9, 4:44 PM
NovoCure Ltd
NVCRNASDAQ
NovoCure rose 11.2% from $11.27 to $12.53, ahead of the S&P 500's +10.5%. Its worst day was Jun 18 (−20.0%), and its low came Feb 9 at $10.03.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
NovoCure closed at its lowest level of the year, 11.0% below where the year started.
−1.1% · S&P 500 +0.5%
EPS of $-0.22 beat the $-0.41 estimate on $174.3M revenue (est. $173.2M); FY revenue guidance of $675.0M–$705.0M against the $670.3M consensus.
Story events cover the past 12 months · Times ET
−8.3% · S&P 500 −0.6%
EPS of $-0.62 missed the $-0.49 estimate on $174.1M revenue (est. $167.8M); FY revenue guidance of $690.0M–$710.0M against the $694.7M consensus.
+27.5% · S&P 500 +1.0%
Novocure (NASDAQ:NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) at the start of
−20.0%, the year's worst day · S&P 500 +1.0%
EPS of $-0.13 beat the $-0.33 estimate on $183.6M revenue (est. $172.6M); FY revenue guidance of $710.0M–$725.0M against the $704.0M consensus.
+28.4%, the year's best day · S&P 500 −1.2%
EPS of $-0.09 beat the $-0.23 estimate on $193.4M revenue (est. $182.4M); FY revenue guidance of $736.0M–$743.0M against the $726.6M consensus.
−7.5% · S&P 500 −0.4%
Where it ended: a close of $12.53 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.21, revenue est. $189.8M).
Nothing in the past 12 months.
All NVCR dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NVCR and SPY from Benzinga historical bars. Not investment advice.
